Skip to main content

Off-label Use of Rituximab and Rituximab Biosimilars: 2 Medicare contractor policies compared

2 Local Coverage Determinations in the current Medicare Coverage Database export carry the title "Off-label Use of Rituximab and Rituximab Biosimilars", between them covering 12 states and territories. 2 of them have a billing and coding article with a diagnosis list, ranging from 49 to 836 covered ICD-10-CM codes. The table below is the fastest way to see which version governs a given state and how far the versions have drifted.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Policies with this title
2
States covered
12
Versions with a coded article
2
Revision dates
2026-04-01 to 2026-07-30

Every version by contractor

Open a version for its full policy text, contracts, codes and related NCDs. Covered codes are the count of ICD-10-CM codes in the version's billing and coding article; a dash means the export attaches no coded article.

Local Coverage Determinations titled "Off-label Use of Rituximab and Rituximab Biosimilars"
LCDContractorStatesRevisedCovered codesPolicy words
L38920CGS Administrators, LLCKY OH2026-07-30491,184
L39297Wellpoint FederalCT IL MA ME MN NH NY RI VT WI2026-04-018361,070

Which diagnoses each contractor covers

Across the 2 versions with a coded billing and coding article, 840 ICD-10-CM codes are covered by at least one contractor: 45 by every version and 795 (95%) by only some of them. L39297 (Wellpoint Federal) covers the most codes no other version lists (791). L38920 (CGS Administrators, LLC) leaves out the most codes that every other version covers (791), the version where a diagnosis accepted elsewhere is most often absent. The comparison is mechanical: it counts codes on the lists and does not weigh the policy text, frequency limits or documentation rules, which can matter as much as the list.

Unique codes appear on that version's covered list only; missing codes are covered by every other version but not by this one. Lists are the union of the coded billing and coding articles linked to each LCD (MCD release 2026-11-12).

Covered ICD-10-CM codes per version of Off-label Use of Rituximab and Rituximab Biosimilars
LCDContractorArticlesCoveredOnly hereMissing
L38920CGS Administrators, LLCA58582494791
L39297Wellpoint FederalA591018367914

Where the lists part

Three-character ICD-10-CM categories ranked by how many of their codes are covered by some versions and not others; a category near the top is where checking the local list matters most.

ICD-10-CM categories with the most codes only some versions of Off-label Use of Rituximab and Rituximab Biosimilars cover
CategoryCategory title (FY2027)Codes that differ
M05Rheumatoid arthritis with rheumatoid factor208
M06Other rheumatoid arthritis98
C82Follicular lymphoma97
C83Non-follicular lymphoma78
C81Hodgkin lymphoma70
C84Mature T/NK-cell lymphomas62
C85Other specified and unspecified types of non-Hodgkin lymphoma40
M33Dermatopolymyositis16
T86Complications of transplanted organs and tissue11
C91Lymphoid leukemia9
M32Systemic lupus erythematosus (SLE)9
L10Pemphigus8

Code-by-contractor sample

100 of the 795 codes covered by some versions and not others, codes that most versions cover first and no more than three per category in the first pass. Y means the version's covered list includes the code.

100 of the 795 ICD-10-CM codes that only some versions of Off-label Use of Rituximab and Rituximab Biosimilars cover
ICD-10-CMDescription (FY2027)L38920L39297
B10.89Other human herpesvirus infection—Y
B20Human immunodeficiency virus [HIV] disease—Y
C79.32Secondary malignant neoplasm of cerebral meninges—Y
C79.40Secondary malignant neoplasm of unspecified part of nervous system—Y
C79.49Secondary malignant neoplasm of other parts of nervous system—Y
C81.00Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site—Y
C81.01Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck—Y
C81.02Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes—Y
C82.00Follicular lymphoma grade I, unspecified site—Y
C82.01Follicular lymphoma grade I, lymph nodes of head, face, and neck—Y
C82.02Follicular lymphoma grade I, intrathoracic lymph nodes—Y
C83.00Small cell B-cell lymphoma, unspecified site—Y
C83.01Small cell B-cell lymphoma, lymph nodes of head, face, and neck—Y
C83.02Small cell B-cell lymphoma, intrathoracic lymph nodes—Y
C84.09Mycosis fungoides, extranodal and solid organ sites—Y
C84.0AMycosis fungoides, in remission—Y
C84.19Sezary disease, extranodal and solid organ sites—Y
C85.10Unspecified B-cell lymphoma, unspecified site—Y
C85.11Unspecified B-cell lymphoma, lymph nodes of head, face, and neck—Y
C85.12Unspecified B-cell lymphoma, intrathoracic lymph nodes—Y
C88.01Waldenstrom macroglobulinemia, in remission—Y
C88.40Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission—Y
C88.41Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission—Y
C91.00Acute lymphoblastic leukemia not having achieved remission—Y
C91.01Acute lymphoblastic leukemia, in remission—Y
C91.02Acute lymphoblastic leukemia, in relapse—Y
C94.40Acute panmyelosis with myelofibrosis not having achieved remission—Y
C94.41Acute panmyelosis with myelofibrosis, in remission—Y
C94.42Acute panmyelosis with myelofibrosis, in relapse—Y
C96.4Sarcoma of dendritic cells (accessory cells)—Y
C96.9Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified—Y
C96.ZOther specified malignant neoplasms of lymphoid, hematopoietic and related tissue—Y
D36.0Benign neoplasm of lymph nodes—Y
D47.1Chronic myeloproliferative disease—Y
D47.9Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified—Y
D47.Z1Post-transplant lymphoproliferative disorder (PTLD)—Y
D59.19Other autoimmune hemolytic anemia—Y
D59.8Other acquired hemolytic anemias—Y
D59.9Acquired hemolytic anemia, unspecified—Y
D68.32Hemorrhagic disorder due to extrinsic circulating anticoagulants—Y
D68.4Acquired coagulation factor deficiency—Y
D69.42Congenital and hereditary thrombocytopenia purpura—Y
D69.49Other primary thrombocytopenia—Y
D76.3Other histiocytosis syndromes—Y
D89.1Cryoglobulinemia—Y
D89.813Graft-versus-host disease, unspecified—Y
D89.84IgG4-related disease—Y
E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm—Y
G04.82Acute flaccid myelitisY—
G61.81Chronic inflammatory demyelinating polyneuritis—Y
G93.49Other encephalopathy—Y
I77.6Arteritis, unspecified—Y
I77.82Antineutrophilic cytoplasmic antibody [ANCA] vasculitis—Y
L10.0Pemphigus vulgaris—Y
L10.1Pemphigus vegetans—Y
L10.2Pemphigus foliaceous—Y
L12.1Cicatricial pemphigoid—Y
L12.2Chronic bullous disease of childhood—Y
L12.30Acquired epidermolysis bullosa, unspecified—Y
L13.0Dermatitis herpetiformis—Y
L13.1Subcorneal pustular dermatitis—Y
L13.8Other specified bullous disorders—Y
L14Bullous disorders in diseases classified elsewhere—Y
L40.1Generalized pustular psoriasis—Y
L51.2Toxic epidermal necrolysis [Lyell]—Y
M05.00Felty's syndrome, unspecified site—Y
M05.011Felty's syndrome, right shoulder—Y
M05.012Felty's syndrome, left shoulder—Y
M06.00Rheumatoid arthritis without rheumatoid factor, unspecified site—Y
M06.011Rheumatoid arthritis without rheumatoid factor, right shoulder—Y
M06.012Rheumatoid arthritis without rheumatoid factor, left shoulder—Y
M30.0Polyarteritis nodosa—Y
M30.1Polyarteritis with lung involvement [Churg-Strauss]—Y
M31.10Thrombotic microangiopathy, unspecified—Y
M31.30Wegener's granulomatosis without renal involvement—Y
M31.31Wegener's granulomatosis with renal involvement—Y
M32.0Drug-induced systemic lupus erythematosus—Y
M32.10Systemic lupus erythematosus, organ or system involvement unspecified—Y
M32.11Endocarditis in systemic lupus erythematosus—Y
M33.00Juvenile dermatomyositis, organ involvement unspecified—Y
M33.01Juvenile dermatomyositis with respiratory involvement—Y
M33.02Juvenile dermatomyositis with myopathy—Y
M34.0Progressive systemic sclerosis—Y
M34.1CR(E)ST syndrome—Y
M34.2Systemic sclerosis induced by drug and chemical—Y
M35.00Sjogren syndrome, unspecified—Y
M35.01Sjogren syndrome with keratoconjunctivitis—Y
M35.02Sjogren syndrome with lung involvement—Y
M36.0Dermato(poly)myositis in neoplastic disease—Y
N02.0Recurrent and persistent hematuria with minor glomerular abnormality—Y
N05.0Unspecified nephritic syndrome with minor glomerular abnormality—Y
N05.2Unspecified nephritic syndrome with diffuse membranous glomerulonephritisY—
N18.6End stage renal disease—Y
R59.0Localized enlarged lymph nodes—Y
R59.1Generalized enlarged lymph nodes—Y
R59.9Enlarged lymph nodes, unspecified—Y
T86.00Unspecified complication of bone marrow transplant—Y
T86.09Other complications of bone marrow transplant—Y
T86.10Unspecified complication of kidney transplant—Y
Z51.6Encounter for desensitization to allergens—Y

Download every covered code with a column per LCD (CSV). The LCD coverage variation report ranks every multi-contractor title by how far its lists diverge.

How to use the comparison

Start from the state where the service is furnished and open that contractor's version; its billing and coding article carries the diagnosis codes the claims system will test. For a group that bills in several jurisdictions, the version with the smallest covered list is the safe common denominator for pre-service review, and the version with the largest list shows what documentation can support an appeal elsewhere. The L39297 version is the one most searched for this title; the LCD lookup guide explains how jurisdictions are assigned, and the LCD hub lists every topic that more than one contractor has written.

For teams evaluating QuickIntell software

Where QuickIntell fits across jurisdictions

For teams working across MAC jurisdictions, evaluate how requirements, source policies and documentation review should be organized for each case. Confirm jurisdiction-specific scope and supported actions during a QuickAuth evaluation; compare claim and denial follow-up separately in QuickRCM.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Why are there 2 LCDs called "Off-label Use of Rituximab and Rituximab Biosimilars"?

Each Medicare Administrative Contractor writes its own Local Coverage Determination for its jurisdiction. 2 contractors publish a policy with this title covering 12 states; they often start from one contractor's text and then revise separately, so dates, criteria and diagnosis lists differ by jurisdiction.

Which "Off-label Use of Rituximab and Rituximab Biosimilars" LCD applies to my claim?

The one written by the contractor that processes the claim: the A/B MAC for the state where the service is furnished, or the DME MAC region for equipment. The table lists each policy's states; open the policy for that jurisdiction and its billing and coding article.

How different are the diagnosis lists?

Across the 2 versions with a coded billing and coding article, 840 ICD-10-CM codes are covered by at least one contractor: 45 by every version and 795 (95%) by only some of them. A diagnosis accepted under one contractor's version can deny under another's, so a group that bills in several jurisdictions checks the list of the contractor that processes each claim.

When were these policies last revised?

Revision effective dates run from 2026-04-01 to 2026-07-30. A claim is judged against the version in force on the date of service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Policy metadata and code counts are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.